Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-06-02
2008-08-12
Nashed, Nashaat T. (Department: 1656)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S194000, C435S069100, C435S252300, C435S320100
Reexamination Certificate
active
07411054
ABSTRACT:
The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
REFERENCES:
patent: 5854067 (1998-12-01), Newgard et al.
patent: 5891717 (1999-04-01), Newgard et al.
patent: 6673549 (2004-01-01), Furness et al.
patent: 6727066 (2004-04-01), Kaser
patent: 7070947 (2006-07-01), Meyers et al.
patent: 7193069 (2007-03-01), Isogai et al.
patent: 2003/0211093 (2003-11-01), Yue et al.
patent: WO 97/26357 (1997-07-01), None
Altschul et al., J. Mol. Biol., 1990, 215:403-410.
Altschul et al.,Nucleic Acids Res.,1997, 25(17):3389-3402.
International Human Genome Sequencing Consortium,Initial sequencing and analysis of the human genome,Nature 1, vol. 409, Feb. 15, 2001.
Karlin et al.,Proc. Natl. Acad. Sci. USA,1990, 87(6):2264-2268.
Karlin et al.,Proc. Natl. Acad. Sci. USA,1993, 90(12):5873-5877.
Myers et al.,CABIOS,1988, 4:11-17.
The Human Genome The Sequence of the Human Genome, Science, vol. 291, Feb. 16, 2001.
Sonnhammer et al.,Proteins,1997, 28(3):405-420.
Weintraub et al.,Trends in Genetics,Jan. 1985.
GenBank Accession No. AK026414; Suzuki, Submitted Aug. 29, 2000.
Deeb et al., “Human Hexokinase II: Sequence and Homology to other Hexokinases”,Biochem. and Biophys. Res. Comm.,197:68-74 (1993).
EMBL Accession No. AI949849, Mar. 14, 2000.
EMBL Accession No. BE159085, Dias Neto et al., Jul. 2, 2000.
EMBL Accession No. AW475040, Mar. 2, 2000.
Katabi et al., “Hexokinase Type II: A Novel Tumor-Specific Promoter for Gene-Targeted Therapy Differentially Expressed and Regularted in Human Cancer Celles”,Human Gene Therapy,10:155-164 (1999).
Mathupala et al., “Arrest of proliferation of highly glycolytic tumors upon Type II hexokinase down regulation via an antisense RNA approach”, Proceedings of the American Association for Cancer Research, 40:22 (1999).
Meyers Rachel E.
Williamson Mark J.
Millennium Pharmaceuticals Inc.
Moore William W.
Nashed Nashaat T.
LandOfFree
25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4016132